Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 255 participants.

Also called NCT03230786

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 255 participants (enrolled count) (from the registry)
Sponsor
KeyBioscience AG (from the registry)
Registry
  • NCT NCT03230786
  • EudraCT 2017-001061-24
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Czechia, Denmark, Moldova, Poland, Romania, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03230786. Randomized; triple masking; primary purpose treatment. Start 2017-08-23 (actual); primary completion 2018-07-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Daily injection of KBP/placebo for 12 weeks as add-on to metformin
Lead sponsor
KeyBioscience AG (class: industry)
Collaborator
Nordic Bioscience A/S (class: industry)

Record details

Record id
cardio:ct-nct03230786
Content hash
473e2af512d76e4eb80e0b85e64d2bd653a0507cc7d2d2a2e25df395240d9f91